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Brexpiprazole is a new atypical antipsychotic for schizophrenia management and as 
adjunct in major depressive disorder (MDD). We searched randomized controlled-
trials (RCT) to review brexpiprazole efficacy and tolerability in acute management of 
schizophrenia and MDD using PubMed, EUDRACT, ClinicalTrials.gov and Cochrane 
Central Register of Controlled-Trials. A meta-analysis was conducted using the 
identified 14 RCT to assess its efficacy using positive and negative syndrome scale 
(PANSS), clinical global impressions – severity of Illness (CGI-S), Personal and 
Social Performance scale (PSP), Montgomery–Åsberg Depression Rating Scale 
(MADRS), Sheehan Disability Scale (SDS) and Hamilton Depression Rating Scale 
(HDRS17). The mean difference (MD) comparing brexpiprazole and placebo were 
PANSS -4.48, CGI-S -0.23 and PSP 3.24 favoring brexpiprazole. Compared to 
aripiprazole and quetiapine, brexpiprazole showed similar efficacy. In MDD, 
brexpiprazole showed efficacy compared to placebo demonstrated by MADRS -1.25, 
SDS -0.37 and HDRS17 -1.28. Brexpiprazole was associated with side effects 
including akathisia RR=1.72; weight increase RR=2.74 and somnolence RR=1.87. 
Compared to 4mg, brexpiprazole 2mg was associated with less risk of akathisia and 
Somnolence. Brexpiprazole demonstrated significant improvements in schizophrenia 
and MDD and is well-tolerated; however, associated with akathisia and somnolence. 
These findings will guide psychiatrists and pharmacists in their clinical role for 
supporting psychiatric patients care. 
 







Schizophrenia is a chronic psychiatric disorder, where patient’s perception and 
behavior are significantly altered; with diagnosis confirmed by a clinical psychiatrist 
after full psychiatric assessment (Reyad & Mishriky, 2019). In England, psychotic 
disorders annual incidence is 32 cases per 100,000 people, 15 of them 
schizophrenia (Kirkbride et al., 2012). The aetiology of schizophrenia is not fully 
understood with genetic and environmental factors involved (Andreasen, 1999) with 
80% of patients have a relapse within 5 years of recovery (Robinson et al., 1999).  
There are two main groups of antipsychotics, typical (first generation) and atypical 
(second generation). First generation antipsychotics (FGA’s) are dopamine (D2) 
receptors antagonists and could block histamine, muscarinic and alpha-1 receptors 
(Ayano, 2016). Second generation antipsychotics (SGA) are serotonin-dopamine 
antagonists (Abi-Dargham & Laruelle, 2005).  5HT-2A antagonism can increase 
dopaminergic neurotransmission in the nigrostriatal pathway, which reduces the risk 
of extrapyramidal symptoms such as akathisia and tardive dyskinesia (Correll, 
Leucht, & Kane, 2004). Second generation antipsychotics are associated with side 
effects such as weight gain, hyperprolactinemia and glucose intolerance (Ndukwe & 
Nishtala, 2017; Sapra et al., 2016). 
Brexpiprazole (Rxulti®, Rexulti®) is a new atypical antipsychotic drug approved in 
2015 by the FDA for the treatment of schizophrenia and as adjunct in major 
depressive disorder (Corponi et al., 2019). Brexpiprazole is a partial agonist of 
dopamine D2 and D3 and serotonin 5HT1A receptors similar to cariprazine, and an 
antagonist of 5HT2A, 5HT2B, 5HT7 and adrenergic receptors (Ward & Citrome, 
2019). It possesses a high affinity for D2, 5HT1A, 5HT2A, α1B, and α2C receptors 




M1 receptors  (Ki > 1000 nM) (Maeda et al., 2014; Ward & Citrome, 2019). 
Brexpiprazole in rats led to low risk of D2 receptor sensitization while inhibiting the 
rebound phenomena related to D2 and 5-HT2A receptors (Amada et al., 2019). 
Compared to aripiprazole, brexpiprazole has lower D2 intrinsic activity, although has 
a more potent serotonergic 5-HT2A antagonism (Fornaro et al., 2019). Brexpiprazole 
also induced neurite outgrowth through 5-HT1A and 5-HT2A receptors and 
subsequent Ca2+ signaling (Ishima et al., 2015). Brexpiprazole completely inhibited 
5-HT neurons firing via 5-HT1A autoreceptors agonism and was more potent than 
aripiprazole (Oosterhof, El Mansari, & Blier, 2014). The high affinity for 5HT1A and 
5HT2A receptors paired with partial D2-agonist activity leads to a favorable side 
effects profile (Frampton, 2019). Brexpiprazole also inhibited rhAChE activity by 
>20% in a concentration-dependent manner with effects more potent than other 
antipsychotics (Obara et al., 2019). Brexpiprazole with fluoxetine produced a rapid 
antidepressant effect in inflammation model of depression with improved alterations 
in BDNF - TrkB signaling and dendritic spine density in the prefrontal cortex (Ma et 
al., 2017). 
Brexpiprazole is primarily metabolized by CYP3A4 and CYP2D6 with inactive major 
metabolite, while mutations around CYP3A4 active site might lead to enzymatic 
activity loss (Chen et al., 2019).  No information is available on the use of 
brexpiprazole during breastfeeding (Brexpiprazole. 2006). Brexpiprazole Cmax and 
AUC showed accumulation of 2.5- to 5.5-fold on day 14, compared to day 1 with 
median tmax 4-5 hours and mean elimination half-life 52-92 hours (Ishigooka et al., 
2018). Brexpiprazole target dose is 2-4 mg/day in schizophrenia and 2 mg in 
depression with dose adjustments considered in hepatic or renal dysfunction (Parikh, 




In this systematic review/meta-analysis, we investigate the efficacy, tolerability and 
safety of Brexpiprazole in adult patients (≥ 18 years) suffering from different 
psychiatric conditions using published randomized controlled-trials (RCT). This meta-
analysis update our knowledge on the role of brexpiprazole in managing 
schizophrenia and depressive symptoms while discussing recent progress in 
establishing its possible role in managing personality disorders, Post traumatic 
Stress Disorder (PTSD) and aggression in Alzheimer disease (AD). 
 
Methods 
Study population and search strategy 
The study population includes adult patients (18 – 65 years old) taking part in phase 
II/III RCT’s assigned to either brexpiprazole 1-4 mg/day, or placebo or active control 
second generation antipsychotic (quetiapine, aripiprazole) for the management of 
schizophrenia and major depressive disorder. A literature search was performed 
using the search terms ‘brexpiprazole’ to search PubMed, EUDRACT, 
ClinicalTrials.gov and Cochrane Central Register of Controlled Trials. No restrictions 
on study size, year of study or duration were set. Titles were screened for relevance 
and duplicates were removed. Abstracts were then screened before the remaining 
relevant full texts were screened to see if they met the inclusion criteria (Figure 1). 
Inclusion and Exclusion Criteria 
Published phase II and III randomized controlled trials that investigate the tolerability, 
safety or efficacy of brexpiprazole in patients suffering from schizophrenia and major 
depressive disorder (MDD) were included (Table 1). All RCT’s were doubled blinded 






The primary efficacy outcomes of brexpiprazole in schizophrenia were Positive and 
Negative Syndrome Scale (PANSS), PANSS Negative and Positive scores, PANSS 
excited Component score, Clinical Global Impressions-Severity of Illness Score 
(CGI-S), Clinical Global Impressions-Improvement (CGI-I),  Personal and social 
Performance scale (PSP) and response rate with mean changes from baseline 
recorded.  Brexpiprazole treatment groups (1-4mg/d) were compared with placebo or 
active control, while brexpiprazole doses outside this range were excluded.  
The primary efficacy outcomes of brexpiprazole in MDD were Montgomery–Åsberg 
Depression Rating Scale MADRS, Sheehan Disability Scale SDS, CGI-S, CGI-I, 
Hamilton Depression Rating Scale HDRS17, MADRS response, MADRS remission, 
CGI-I response, response rate with mean changes from baseline recorded.  
Brexpiprazole treatment groups (1-4mg/d) were compared with placebo or active 
control, while brexpiprazole doses outside this range were excluded.  The primary 
tolerability and safety outcomes for brexpiprazole were discontinuation due to 
adverse effects and adverse events.  
Statistical Methods  
Review Manager 5.3 (RevMan) along with the Cochrane Collaboration tool for 
assessing the risk of bias (Higgins et al., 2011; The Nordic Cochrane Centre, The 
Cochrane Collaboration, 2014) were used to assess the levels of selection, 
performance, detection, attrition and reporting bias in each of the RCT’s. 
‘Characteristics of study’ tables were completed in RevMan for each of the individual 
studies and a summary table was created (The Nordic Cochrane Centre, The 
Cochrane Collaboration, 2014). Funnels plots for each of the outcomes were also 




The inverse variance method with random effects model was used to calculate the 
mean differences for continuous outcomes (PANSS, PANSS Negative and Positive 
scores, PANSS excited Component score, CGI-S, CGI-I, PSP, MADRS, SDS, 
HDRS17). The Mantel-Haenszel method with random effects model was used to 
calculate the risk ratio for all dichotomous outcomes (MADRS response, MADRS 
remission, CGI-I response, response rate, risk of discontinuation due to adverse 
effects and common side effects) (Egger, Smith, & Altman, 2001). RevMan was used 
for all statistical analysis, 95% confidence intervals were used for all outcomes and 
p-value <0.05 was regarded as statistically significant (The Nordic Cochrane Centre, 
The Cochrane Collaboration, 2014). 
Results  
Search Results and Included Studies 
Figure 1 shows the selection process of RCT’s included. PubMed, EUDRACT, 
ClinicalTrials.gov and Cochrane Central Register of Controlled Trials were searched 
for ‘brexpiprazole’ giving 399 records in total. After removing duplicates and 
screening titles and abstracts, 19 studies were included in full text screening; while 
14 RCTs met the inclusion criteria (Seven for schizophrenia acute management and 
Seven as adjunct in the management of MDD) (Citrome et al., 2016; Correll et al., 
2015; Hobart, Skuban, Zhang, Augustine et al., 2018; Hobart, Skuban, Zhang, 
Josiassen et al., 2018; Ishigooka, Iwashita, & Tadori, 2018; Kane et al., 2015; 
NCT00797966, 2016; NCT00905307, 2015; NCT01052077, 2015; NCT01810380, 
2017; NCT01838681, 2017; NCT02194933, 2018; Thase, Youakim, Skuban, Hobart, 





Table 1 shows the characteristics of the included RCTs; all of them were double 
blinded. Treatment duration was 6 weeks in schizophrenia management and MDD 
and brexpiprazole dose ranged from 1 to 4mg/day. Studies were undertaken in 
regions including USA, Russia, Ukraine and India with similar prevalence and 
incidence rates to the UK (Steel et al., 2014).  
For the risk of bias; the sequence generation, allocation concealment and blinding 
were mostly with ‘unclear’ risk due to insufficient information. The patients in all the 
studies were randomly assigned and there was certain level of blinding for both 
participants and personnel. The domains relating to the completeness of data and 
reporting of outcomes were ‘low’ risk of bias (data not shown).  
 
Efficacy of Brexpiprazole in the management of Schizophrenia 
7 RCTs for brexpiprazole role in schizophrenia management were included in this 
meta-analysis, 5 RCTs, where brexpiprazole was compared with placebo (including 
two trials (NCT00905307, 2015; NCT01810380, 2017) also containing active control) 
with a total of 1618 patients treated with brexpiprazole compared to 742 patients who 
received placebo and 3 RCTs, where brexpiprazole was compared with active 
control (Citrome et al., 2016; NCT00905307, 2015; NCT01810380, 2017) with a total 
of 486 patients treated with brexpiprazole compared to 236 patients who received 
active control. All the trials included in brexpiprazole role in schizophrenia 
management assessed PANSS, PANSS positive, PANSS negative, CGI-I, CGI-S, 
response rate, while Four RCTs assessed PSP (Figure 2). 
The mean change from baseline in PANSS total score was significantly greater for 
brexpiprazole compared to placebo, with a mean difference (MD) of -4.48 [95% 




(Figure 2A). The forest plot shows the mean differences for all the studies 
individually favor brexpiprazole, with low heterogeneity between the studies (x2=10.5, 
I2=0%). Similarly, PANSS positive score MD was significantly greater for 
brexpiprazole -0.99 [95% CI -1.45, -0.52] favoring brexpiprazole treatment 
(p<0.00001) (Figure 2B) with moderate heterogeneity (x2=20.3, I2=46%), while 
PANSS negative score, MD -1.16 [95% CI -1.51, -0.80] favoring brexpiprazole 
(p<0.00001) (Figure 2C).  
CGI-S mean change from baseline was also significantly greater for brexpiprazole 
MD -0.23 [95% CI -0.31, -0.15], p<0.00001, which was clinically and statistically 
significant (Figure 2D) with very low heterogeneity between the studies (I2=0%). 
PANSS excited Component, CGI-I and response rate also supported brexpiprazole 
efficacy in management of schizophrenia compared to placebo (Table 2).   
Four RCTs measured the effect of brexpiprazole on PSP scale (Figure 2E), showing 
positive effect MD 3.24 [95% CI 2.22, 4.25], with very low heterogeneity (I2=0%).  
When compared to active control (aripiprazole and quetiapine), brexpiprazole 
showed similar efficacy to these two SGA as highlighted by the changes in PANSS, 
PANSS positive, PANSS negative, CGI-I, CGI-S, PSP scales and response rate 
(Figure 2F, Table 2). 
Brexpiprazole 2mg and 4 mg doses were compared in four RCT (Correll et al., 2015; 
Ishigooka et al., 2018; Kane et al., 2015; NCT02194933, 2018), where both 
brexpiprazole doses showed similar efficacy in schizophrenia management (Table 
4).  
 





7 RCTs for brexpiprazole role in MDD were included, where brexpiprazole was 
compared with placebo (including one trial (Hobart et al., 2018) containing active 
control) with a total of 1783 patients treated with brexpiprazole compared to 1577 
patients who received placebo. All the Seven trials assessed MADRS, SDS, CGI-S, 
MADRS response, MADRS remission, while Six assessed CGI-I, CGI-I response 
and Five assessed HDRS17 (Figure 3, Table 2). 
The mean change from baseline in MADRS score was significantly greater for 
brexpiprazole compared to placebo, MD -1.25 [95% CI -1.74, -0.76] favouring 
brexpiprazole (p<0.00001) (Figure 3A). All the studies individually favour 
brexpiprazole, with low heterogeneity between the studies (X2=4.82, I2=0%). 
SDS mean change was significantly greater for brexpiprazole compared to placebo, 
with MD -0.37 [95% CI -0.52, -0.21] (p<0.00001) (Figure 3B). Similar positive 
outcomes for brexpiprazole are highlighted as changes in CGI-S score (MD -0.19[-
0.27, -0.11]) (Figure 4C), HDRS17 (MD -1.28[-1.79, -0.76]) (figure 4D), CGI score 
(MD -0.21 [-0.30, -0.12]), MADRS response (MD 1.36 [1.20, 1.55]) , CGI-I response 
(MD 1.29 [1.18, 1.41])  and MADRS remission (MD 1.36 [1.16, 1.61])  (Table 2). 
 
Tolerability and Safety of Brexpiprazole compared to Placebo in the 
management of Schizophrenia and Major Depressive Disorder  
In a total of 3401 patients treated with brexpiprazole compared to 3514 patients who 
received placebo, the overall risk ratio for trial discontinuation due to adverse effects 
is 0.90 [0.74 to 1.10], p=0.30 (Figure 4A). There is variation among the studies with 
some favoring brexpiprazole, while others favoring placebo; with a moderate to high 
heterogeneity (I2 = 53%). Brexpiprazole was associated with some side effects 




[2.16 to 3.48], p<0.00001 and somnolence RR=1.87 [1.30 to 2.71], p=0.0008 (Figure 
4, Table 3). 
Brexpiprazole in patients suffering from MDD was also associated with restlessness 
RR=4.11 [2.19 to 7.71], p<0.00001, increased appetite RR=3.88 [1.47 to 10.3], 
p=0.006 and in patients suffering from schizophrenia, brexpiprazole was associated 
with nausea RR=2.58 [1.34 to 5.00], p=0.005. 
Compared to brexpiprazole 4 mg, brexpiprazole lower dose (2mg) was associated 
with less risk of akathisia 22/501 compared to 32/496 (RR=0.68); Somnolence 7/387 
vs 13/383 (RR=0.53) and trial withdrawal due to adverse events 38/482 vs 48/477 
(RR=0.78) (Table 4). 
 
Tolerability and Safety of Brexpiprazole compared to Active control in 
the management of Schizophrenia and MDD  
3 trials were identified comparing brexpiprazole with active control (aripiprazole and 
quetiapine) in schizophrenia management and only one trial comparing 
brexpiprazole with active control (quetiapine) in MDD. In a total of 683 patients 
treated with brexpiprazole compared to 336 patients who received active control, the 
overall risk ratio for trial discontinuation due to adverse effects is 1.43 [0.84 to 2.42], 
p=0.19 (Table 3) and reduced risk of dry mouth RR=0.27 [0.12 to 0.61], p=0.002.  
Brexpiprazole compared with quetiapine was associated with less risk of 
somnolence RR=0.25 [0.15 to 0.43], p<0.00001, dry mouth RR=0.16 [0.05 to 0.48], 
p=0.001 and weight increase RR=0.59 [0.32 to 1.08], p=0.09 and higher risk of 
Akathisia RR=1.73 [0.79 to 3.79], p=0.17 (Table 3). 
 




Currently, there are several RCT trials studying the role of brexpiprazole in the 
management of bipolar disorders, post-traumatic stress disorder, personality 
disorders and agitation in AD patients.  
Brexpiprazole (3mg/day) was effective in the management of irritability co-morbidity 
with MDD as shown in changes of Sheehan Irritability Scale total and item 1 (irritable 
mood) scores (NCT01942785) (Fava et al., 2016). A modest reduction in impulsivity 
was observed with brexpiprazole, but not aripiprazole (Citrome et al., 2016). 
Brexpiprazole has shown promising preliminary results in managing agitation in 
dementia (Garay et al., 2016), while improving cognitive dysfunction in animal 
models through 5-HT1A receptor-mediated increase in neuron activity (van den 
Munkhof, H E et al., 2017). Open-label results support the anxiolytic effects of 
adjunctive brexpiprazole as determined by changes in HAM-A scale (Davis et al., 
2016).  
Results from one RCT (NCT03257865) published recently regarding brexpiprazole 
efficacy in bipolar disorders (change from baseline in Young-Mania Rating Scale 
(YMRS) score at week 3 was -12.3 (162 patients) compared with -10.7 for placebo (168 
patients) with increased risk of akathisia and insomnia for brexpiprazole (NCT03257865, 
2020); the clinical field is still awaiting another two trials (NCT03287869 and 
NCT03259555) results to be released to establish brexpiprazole role in bipolar 
disorders management.  
In a pilot study, brexpiprazole was effective in bipolar depression with decrease in 
MADRS score and improvement of quality of life; however YMRS and cognitive 
scores did not change significantly (Brown et al., 2019). In a rat model of PTSD, 
brexpiprazole with escitalopram exhibited a lower anxiety index and reduced startle 






This systematic review/meta-analysis investigated the efficacy and safety of 
brexpiprazole for the management of psychiatric conditions including schizophrenia 
and MDD using the available clinical trials. Brexpiprazole improved PANSS total and 
subscales- psychiatric scales used for measuring symptom severity in patients with 
psychosis. Brexpiprazole also showed significant improvements in CGI-S, MADRS 
and HDRS17. As far as our awareness, this meta-analysis covered the role of 
brexpiprazole in different psychiatric conditions and our results update and are in 
consistency with previous meta-analysis that showed brexpiprazole significant 
efficacy (Citrome, 2015). Our results confirm brexpiprazole superiority in 
management of schizophrenia over placebo (Table 2) with similar efficacy to SGA 
such as quetiapine and aripiprazole (Table 2). Our data also confirm brexpiprazole 
role as adjunct to antidepressant in improving functioning in patients with MDD 
(Hobart, Zhang, Weiss et al., 2019) and are in agreement with another meta-analysis 
(Kishi et al., 2019), however, this meta-analysis did not include some of the recent 
trials included in our meta-analysis especially in the management of MDD. 
Brexpiprazole was well-tolerated and associated with moderate side effects such as 
increased risk of akathisia and somnolence, weight increase, dry mouth and nausea 
(Table 3, Figure 5). Brexpiprazole compared with quetiapine was associated with 
less risk of somnolence, dry mouth and weight increase (Table 3, Figure 4) as 
brexpiprazole has moderate affinity for histamine H1 receptors with very low affinity 
for muscarinic M1 receptors. Brexpiprazole 2mg lower dose had similar efficacy to 
the higher 4mg dose, but with less risk of akathisia and somnolence, in agreement 
with finding of a previous meta-analysis (Kishi et al., 2019). In clinical practice, 




all-cause medical costs compared with quetiapine (Broder et al., 2019) and did not 
increase QT interval (Aronow & Shamliyan, 2018). Brexpiprazole is considered to 
have a favorable side effects profile mainly due to its high affinity for 5HT1A and 
5HT2A receptors with partial D2-agonist activity (Frampton, 2019).  
Adults with insufficient outcomes on aripiprazole or bupropion benefit from switching 
to brexpiprazole (Aladeen et al., 2018) and in patients with inadequate response to 
antidepressant and sleep disturbances, adjunctive brexpiprazole improved 
physiologic measures of sleep and daytime alertness (Krystal et al., 2016).  
Currently, brexpiprazole is under investigation for management of other psychiatric 
conditions such as bipolar disorders, borderline personality, agitation in AD and 
PTSD and in combination with osimertinib was shown as a potential therapy for brain 
tumors with poor prognosis.  
This systematic review/meta-analysis shows that brexpiprazole is well tolerated and 
significantly improves schizophrenia and MDD; however, the results need to be 
interpreted with caution as the treatment length was short (6 weeks), with several 
doses of brexpiprazole used with different efficacy and side effects profile. The scant 
evidence regarding long term usage of brexpiprazole highlighted its association with 
mild or moderate in severity side effects such as weight increase (17.7%) -mean 
increase in body weight was 2.7 kg,  somnolence (8.0%), headache (7.2%), 
akathisia (6.7%), increased appetite (6.3%), insomnia (6.3%), fatigue (6.1%) and 
anxiety (5.2%) (Hobart, Zhang, Skuban et al., 2019). In elderly, adjunctive 
brexpiprazole was generally well tolerated with improvements in depressive 
symptoms and social functioning (Lepola et al., 2018). Therefore, it is recommended 




more comprehensive understanding of brexpiprazole role in the management of 
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Table 1 Randomized Controlled trials included in the meta-analysis (all are double blinded 
RCT): Brex: Brexpiprazole, Que: Quetiapine, Ari: Aripiprazole 
 










Schizophrenia 6 Placebo     
Brex   2mg/day 
Brex 4mg/day 







Schizophrenia 6 Placebo                    







Kane 2015 NCT01393613 Placebo 
control 
Schizophrenia 6 Placebo                    







NCT00905307  Placebo  
Ari 
Controlled 
Schizophrenia 6 Placebo                    









NCT01810380  Placebo 
Quetiapine 
controlled 
Schizophrenia 6 Placebo                    
Brex 2-
4mg/day            
Que 400-
800mg/day              
163           
151                                                                                                                                                                                          
 
154 
Citrome 2016 NCT02054702 Aripiprazol
e controlled 
Schizophrenia 6 Brex                    
Arip              
64                                                                                                                                                                                          
33 
NCT02194933  Double 
blinded 






















































































































CGI-S -0.23 (-0.31, -0.15) <0.00001* 
CGI score -0.2 (-0.34, -0.06) 0.005* 
PANSS positive -0.99  (-1.45, -0.52) <0.00001* 
PANSS negative -1.16 (-1.51, -0.8) <0.00001* 
PANSS excited 
component 
-0.76 (-1.09, -0.43) <0.00001* 
Response rate 1.31 (1.19, 1.43) <0.00001* 















































CGI-S 0.04 (-0.13, 0.21) 0.66 
CGI score 0.13 (-0.07, 0.34) 0.2 
PANSS negative -0.01 (-0.79, -0.78) 0.99 
PSP -0.78 (-2.74,1.19) 0.44 




and active control 



















































SDS -0.37 (-0.52, -0.21) <0.00001* 
CGI-S -0.19 (-0.27, -0.11) <0.00001* 
HDRS17 -1.28 (-1.79, -0.76) <0.00001* 
CGI-I score -0.21 (-0.30, -0.12) <0.00001* 
MADRS response 1.36 (1.20, 1.55) <0.00001* 






1.36 (1.16, 1.61) 0.0002* 
 
Table 3: Safety and Tolerability of Brexpiprazole 
Compared 
to 









due to Adverse 
Events 
0.90 (0.74, 1.10) 0.30 
Weight increase 2.74 (2.16, 3.48) <0.00001* 
Akathisia 1.72 (1.38, 2.14) <0.00001* 
Headache 0.89 (0.76, 1.05) 0.18 
Somnolence 1.87 (1.30, 2.71) 0.0008* 









due to Adverse 
Events 
1.67 (0.77, 3.63) 0.19 
Weight increase 0.59 (0.32, 1.08) 0.09 
Akathisia 1.73 (0.79, 3.79) 0.17 
Headache 1.64 (0.61, 4.36) 0.32 
Somnolence 0.25 (0.15, 0.43) <0.00001* 











due to Adverse 
Events 
1.25 (0.61, 2.58) 0.54 
Weight increase 1.22 (0.64, 2.35) 0.55 
Akathisia 1.28 (0.69, 2.38) 0.43 
Headache 1.38 (0.75, 2.56) 0.3 
Somnolence 4.63 (0.86, 24.9) 0.07 









Table 4: Efficacy and safety of Brexpiprazole 2mg compared to Brexpiprazole 4mg in 
schizophrenia management  
Psychiatric 
Scale  
MD (CI)/ RR (CI) p-value Comments 
PANSS total 0.5 (-1.87, 2.88) 0.68 Brexpiprazole 2 
and 4 mg doses 
show similar 
efficacy  
CGI-S -0.03 (-0.11, 0.17) 0.67 
CGI score -0.29 (-0.57, -0.01) 0.05 
PANSS positive 0.23  (-0.59, 1.05) 0.59 
PANSS negative -0.18 (-0.79, 0.43) 0.56 
PSP -0.67 (-2.38, 1.03) 0.44 
Weight increase 1.08 (0.68, 1.70) 0.75 Brexpiprazole 
2mg has fewer 
incidences of side 
effects compared 
to higher dose 
(4mg), albeit not 
statistically 
significant. 
Akathisia 0.68 (0.40, 1.15) 0.15 
Headache 1.05 (0.72, 1.55) 0.79 
Somnolence 0.53 (0.22, 1.32) 0.17 
Insomnia  0.95 (0.64, 1.40) 0.78 
Trial withdrawal 
due to adverse 
events 







Figure 1: Flowchart summarizing the studies selection process. 
 
Figure 2: Funnel plots for Efficacy of Brexpiprazole in the management of 
Schizophrenia determined by the changes from baseline for (A) Positive and 
Negative Syndrome Scale (PANSS) total score compared with placebo; (B) PANSS 
positive compared with placebo; (C) PANSS negative compared with placebo; (D) 
Clinical Global Impressions – Severity of Illness (CGI-S) compared with placebo; (E) 
Personal and Social Performance (PSP) compared with placebo and (F)  PANSS 
total score compared with active controls. 
 
Figure 3: Funnel Plots for Efficacy of Brexpiprazole in the management of Major 
Depressive Disorders determined by the changes from baseline for (A) Montgomery 
Asberg depression rating scale (MADRS); (B) Sheehan Disability Scale (SDS) 
Clinical Global Impressions – Severity of Illness Score; (C) Clinical Global 
Impressions – Severity of Illness (CGI-S); (D) Hamilton-D rating scale for depression 
(HDRS17) 
 
Figure 4: Funnel Plots for Tolerability and Safety of Brexpiprazole (A) 
Discontinuation from Trials due to Adverse Events; (B) Side Effect-weight Increase; 
(C) Side Effect-Akathisia; (D) Side Effect-Somnolence. 
 
